26-DeoxyacteinCAS# 264624-38-6 |
- 23-epi-26-Deoxyactein
Catalog No.:BCN0314
CAS No.:501938-01-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 264624-38-6 | SDF | Download SDF |
| PubChem ID | 10974362 | Appearance | Powder |
| Formula | C37H56O10 | M.Wt | 660.83 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Synonyms | 26-Deoxyactein; 27-Deoxyactein | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC1CC2(C3C(O3)(CO2)C)OC4C1C5(C(CC67CC68CCC(C(C8CCC7C5(C4)C)(C)C)OC9C(C(C(CO9)O)O)O)OC(=O)C)C | ||
| Standard InChIKey | GCMGJWLOGKSUGX-RBKCHLQLSA-N | ||
| Standard InChI | InChI=1S/C37H56O10/c1-18-12-37(30-33(6,47-30)17-43-37)46-21-13-32(5)23-9-8-22-31(3,4)24(45-29-28(41)27(40)20(39)15-42-29)10-11-35(22)16-36(23,35)14-25(44-19(2)38)34(32,7)26(18)21/h18,20-30,39-41H,8-17H2,1-7H3/t18-,20-,21+,22+,23+,24+,25-,26+,27+,28-,29+,30-,32+,33-,34-,35-,36+,37+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. 23-epi-26-Deoxyactein can inhibit growth of the MCF7 human breast cancer cells and induce cell cycle arrest at G1. 2. 23-epi-26-Deoxyactein has anti-inflammatory activity, it inhibits nitric oxide production by reducing iNOS expression without affecting activity of the enzyme. |
| Targets | CDK | p21 | NOS | NO | p65 | NF-kB |
26-Deoxyactein Dilution Calculator
26-Deoxyactein Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5132 mL | 7.5662 mL | 15.1325 mL | 30.265 mL | 37.8312 mL |
| 5 mM | 0.3026 mL | 1.5132 mL | 3.0265 mL | 6.053 mL | 7.5662 mL |
| 10 mM | 0.1513 mL | 0.7566 mL | 1.5132 mL | 3.0265 mL | 3.7831 mL |
| 50 mM | 0.0303 mL | 0.1513 mL | 0.3026 mL | 0.6053 mL | 0.7566 mL |
| 100 mM | 0.0151 mL | 0.0757 mL | 0.1513 mL | 0.3026 mL | 0.3783 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- MRS 1754
Catalog No.:BCC7473
CAS No.:264622-58-4
- MRS 1706
Catalog No.:BCC7120
CAS No.:264622-53-9
- SSR 146977 hydrochloride
Catalog No.:BCC7635
CAS No.:264618-38-4
- PR-619
Catalog No.:BCC3627
CAS No.:2645-32-1
- Bz-Arg-OEt.HCl
Catalog No.:BCC2686
CAS No.:2645-08-1
- Methyl 2,2-dithienylglycolate
Catalog No.:BCC9034
CAS No.:26447-85-8
- Oxypeucedanin hydrate
Catalog No.:BCN2698
CAS No.:2643-85-8
- 6',7'-Dihydroxybergamottin
Catalog No.:BCN5142
CAS No.:264234-05-1
- Methyl 5-{2-[(tert-butylamino)carbothioyl]carbohydrazonoyl}-1-(2,4-difluorophenyl)-1H-pyrazole-4-carboxylate
Catalog No.:BCC7906
CAS No.:264233-05-8
- SB 415286
Catalog No.:BCC3651
CAS No.:264218-23-7
- Z-Orn-OH
Catalog No.:BCC2757
CAS No.:2640-58-6
- DPPA (Kg)
Catalog No.:BCC2690
CAS No.:26386-88-9
- Humulone
Catalog No.:BCN2682
CAS No.:26472-41-3
- Catharanthine Tartrate
Catalog No.:BCN2462
CAS No.:2648-21-5
- 6-Deoxyisojacareubin
Catalog No.:BCN7723
CAS No.:26486-92-0
- Cyclo(D-Phe-L-Pro)
Catalog No.:BCN4011
CAS No.:26488-24-4
- Clovanediol
Catalog No.:BCN5143
CAS No.:2649-64-1
- Clovanediol diacetate
Catalog No.:BCN5144
CAS No.:2649-68-5
- Nandrolone laurate
Catalog No.:BCC9088
CAS No.:26490-31-3
- Z-Gln-OH
Catalog No.:BCC2783
CAS No.:2650-64-8
- Methyleugenolglycol
Catalog No.:BCN6562
CAS No.:26509-45-5
- N-[Bis(methylthio)methylene]- p-toluenesulfonamide
Catalog No.:BCC9069
CAS No.:2651-15-2
- Taiwanhomoflavone A
Catalog No.:BCN6853
CAS No.:265120-00-1
- Fosaprepitant dimeglumine salt
Catalog No.:BCC4954
CAS No.:265121-04-8
Growth inhibitory activity of extracts and purified components of black cohosh on human breast cancer cells.[Pubmed:14758092]
Breast Cancer Res Treat. 2004 Feb;83(3):221-31.
The purpose of this study was to determine whether black cohosh contains constituents that inhibit the growth of human breast cancer cells, and therefore might eventually be useful in the prevention or treatment of breast cancer. Black cohosh rhizomes were extracted with methanol/water and fractionated by solvent-solvent partitioning to yield three fractions: hexane, ethyl acetate and water. The ethyl acetate fraction displayed the highest potency in two cell-based assays, growth inhibition and cell cycle analysis. This fraction inhibited growth of both the ER+ MCF7 and ER-MDA-MB-453 human breast cancer cell lines with IC50 values of about 20 and 10 micro g/ml, respectively. It also induced cell cycle arrest at G1 when tested at 30 micro g/ml and at G2/M at 60 micro g/ml in MCF7 cells. This suggests that the extract contains a mixture of components with the more active (or more abundant) causing G1 arrest and the less active causing G2/M arrest. We then examined specific components in this extract. The triterpene glycoside fraction obtained by polyamide column chromatography, and the specific triterpene glycosides actein, 23-epi-26-Deoxyactein and cimiracemoside A, inhibited growth of the MCF7 human breast cancer cells and induced cell cycle arrest at G1. The most potent compound, actein, decreased the level of cyclin D1, cdk4 and the hyperphosphorylated form of the pRb protein and increased the level of p21cip1 in MCF7 cells, changes that may contribute to the arrest in G1. Further studies are in progress to identify the mechanisms by which actein and related compounds present in black cohosh inhibit growth of human breast cancer cells.
Inhibition of inducible nitric oxide synthesis by Cimicifuga racemosa (Actaea racemosa, black cohosh) extracts in LPS-stimulated RAW 264.7 macrophages.[Pubmed:19703353]
J Pharm Pharmacol. 2009 Aug;61(8):1089-96.
OBJECTIVES: Cimicifuga racemosa (Actaea racemosa, black cohosh) is used as an anti-inflammatory, antipyretic and analgesic remedy in traditional medicines. The present study focuses on the effects of C. racemosa root extracts on inducible nitric oxide synthase (iNOS) in lipopolysaccharide-stimulated murine macrophages (RAW 264.7). METHODS: C. racemosa rhizome and phosphate-buffered saline extracts were analysed for phenolcarboxylic acids and triterpene glycosides using an HPLC photodiode array/evaporative light-scattering detector system. iNOS was characterised by measurement of iNOS protein (immunoblotting), iNOS mRNA (semiquantitative competitive RT-PCR), nitric oxide production (nitrite levels) and nuclear translocation of nuclear factor-kappaB (p65 subunit) protein. KEY FINDINGS: Incubation of lipopolysaccharide-stimulated macrophages with aqueous C. racemosa extracts (0-6 mg/ml) inhibited nitrite accumulation in a concentration-dependent manner. C. racemosa extracts also reduced iNOS protein expression and iNOS mRNA levels in a dose-dependent manner. C. racemosa extracts did not significantly inhibit iNOS activity and did not affect nuclear translocation of nuclear factor-kappaB (p65 subunit) protein. Incubation with the extract was associated with a concentration-dependent reduction of interferon beta and interferon regulatory factor 1 mRNA. Among the triterpene glycosides, 23-epi-26-Deoxyactein was identified as an active principle in C. racemosa extracts. CONCLUSIONS: Extracts from the roots of C. racemosa inhibit nitric oxide production by reducing iNOS expression without affecting activity of the enzyme. This might contribute to the anti-inflammatory activities of C. racemosa.
